The DOI matches its Crossref record.
Primaquine radical cure of Plasmodium vivax: a critical review of the literature
Open accessAbstract
Background: Primaquine has been the only widely available hypnozoitocidal anti-malarial drug for half a century. Despite this its clinical efficacy is poorly characterized resulting in a lack of consensus over the optimal regimen for the radical cure of Plasmodium vivax. Methods: Published studies since 1950 of the use of primaquine regimens for preventing P. vivax relapse were reviewed. Data were extracted systematically from available papers. Primaquine regimens were categorized according to the total dose administered: very low (≤2.5 mg/kg), low (>2.5 mg/kg- < 5.0 mg/kg) and high (≥ 5.0 mg/kg). The risk of recurrent infection were summarized across geographical regions and the odds ratios between treatment regimens calculated after stratifying by total treatment dose and duration of study follow up. Results: Data could be retrieved from 87 clinical trials presenting data in 59,735 patients enrolled into 156 treatment arms, conducted in 20 countries. There was marked heterogeneity in study design, particularly primaquine dosing and duration of follow up. The median rate of recurrence following very low dose of primaquine (n = 44) was 25% (range 0-90%) at 4–6 months, compared to 6.7 % (range 0-59%) following low dose primaquine (n = 82). High dose primaquine regimens were assessed in 28 treatment arms, and were associated with a median recurrence rate of 0% (Range: 0-15%) at one month. In 18 studies with control arms, the effectiveness of a very low dose primaquine regimen was no different from patients who did not receive primaquine (OR = 0.60, 95%CI 0.33-1.09, p = 0.09), whereas for the low dose regimens a significant difference was reported in 50% (6/12) of studies (overall OR = 0.14, 95%CI: 0.06-0.35, p < 0.001). Two studies enrolling 171 patients demonstrated high effectiveness of high dose primaquine compared to a control arm (OR = 0.03 (95%CI: 0.01-0.13); p < 0.0001). Conclusions: Low dose regimens retain adequate efficacy in some areas, but this is not uniform. The efficacy and safety of pragmatic high dose primaquine regimens needs to be assessed in a range of endemic and geographical locations. Such studies will require a prolonged period of follow up and comparison with control arms to account for confounding factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The changing epidemiology of malaria elimination: New strategies for new challenges
Cotter, C., Sturrock, H. J., Hsiang, M. S., Liu, J., Phillips, A. A., Hwang, J., Gueye, C. S., Fullman, N., Gosling, R. D., & Feachem, R. G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60310-4 · Cited by 671
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis
Price, R. N., von Seidlein, L., Valecha, N., Nosten, F., Baird, J. K., & White, N. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70855-2 · Cited by 388
Self-citationPlasmodium vivax in the Era of the Shrinking P. falciparum Map
Price, R. N., Commons, R. J., Battle, K. E., Thriemer, K., & Mendis, K. (2020) · Trends in Parasitology · doi:10.1016/j.pt.2020.03.009 · Cited by 269
Self-citationFavism and Glucose-6-Phosphate Dehydrogenase Deficiency
Luzzatto, L., & Arese, P. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1708111 · Cited by 267
Malaria ecology along the Thailand-Myanmar border.
Parker, D. M., Carrara, V. I., Pukrittayakamee, S., McGready, R., & Nosten, F. H. (2015) · Malaria Journal · doi:10.1186/s12936-015-0921-y · Cited by 142
“Testing for G6PDd has until recently been possible only in laboratory settings.”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- John, G. K., Douglas, N. M., von Seidlein, L., Nosten, F., Baird, J. K., White, N. J., & Price, R. N.
- Venue
- Malaria Journal
- Published
- 2012-08-17
- Volume
- 11
- Issue
- 1
- Pages
- 280-280
- ISSN
- 1475-2875 (ISSN-L)
- OpenAlex
- W2161252729
- Cited by
- 192
- References
- 0
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primaquine radical cure of Plasmodium vivax: a critical review of the literature. https://app.cochat.ai/papers/10.1186/1475-2875-11-280
- The paper
- John, G. K., Douglas, N. M., von Seidlein, L., Nosten, F., Baird, J. K., White, N. J., & Price, R. N. (2012). Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malaria Journal. https://doi.org/10.1186/1475-2875-11-280
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.